

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 4, 2003

Date of Deposit

Bonnie Stein
Signature

EL 721892421 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: **FRAV2002/0034US NP**
INVENTORS: **Maxime LAMPILAS, et al.**
TITLE: **Novel Heterocyclic Compounds, Their Preparation and Their Use as Medicaments, in Particular as Antibacterials and Beta-Lactamase Inhibitors**

APPLICATION ELEMENTS

17858 U.S. PTO
10/727911
120403

1. ☒ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Specification
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the DisclosureTotal Pages 137
3. ☐ Drawing(s) (35 U.S.C. 113)
Total Sheets 0
4. Oath or Declaration
a. ☒ Newly **unexecuted** (original or copy)
b. ☐ Copy from a prior application (37 CFR § 1.63(d))
i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).
5. Power of Attorney
a. ☐ Newly executed (original or copy)
b. ☐ Copy from a prior application (37 CFR § 1.63(d))
Total Pages
6. ☐ Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission

(if applicable, all necessary)

- a. ☐ Computer Readable Copy
 b. ☐ Paper Copy (identical to computer copy)
 c. ☐ Statement verifying identity of above copies

☐ If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part

of prior application no: _____, filed _____,

Examiner _____, Group/Art Unit _____.

(The cross reference has been/will be inserted on page one of the specification).

☒ This application claims the benefit of French priority application No. 02 15428 filed December 6, 002 and the benefit of U.S. Provisional Application No. 60/484,323, filed July 2, 2003. (The cross reference has been/will be inserted on page one of the specification).

☐ **Incorporation By Reference** (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS


7. ☒ Assignment Papers (cover sheet & document(s)) – 2 pages
 8. ☐ 37 CFR §3.73(b) Statement (when there is an assignee)
 9. ☐ Verified English Translation Document (if applicable)
 10. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
 11. ☐ Preliminary Amendment
 12. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
 13. ☐ *Small Entity Statement(s) ☐ Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)
 14. ☒ Certified Copy of Priority Document – **FR 02 15428** (if foreign priority is claimed)
 15. ☒ Other: Application Data Sheet – 4 pages

CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)


 Irving Newman, Reg. No. 22,638
 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
 Patent Department
 Route #202-206 / P.O. Box 6800
 Bridgewater, New Jersey 08807-0800
 Telephone (908) 231-2785
 Telefax (908) 231-2626
 Aventis Docket No. **FRAV2002/0034US NP**

FEE TRANSMITTAL for FY 2004

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 1148

Complete if Known

Application Number	To Be Assigned
Filing Date	Filed C ncurrently Herewith
First Named Inventor	Maxim LAMPILAS
Examiner Name	Not Yet Assigned
Group / Art Unit	Not Yet Assigned
Attorney Docket No.	FRAV2002/0034US NP

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account

Deposit Account Number
Deposit Account Name

18-1982

Aventis Pharmaceuticals Inc.

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Fee Code	Fee (\$)	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
	1001	770		2001	375	Utility filing fee	770
	1002	340		2002	165	Design filing Fee	
	1003	530		2003	260	Plant filing fee	
	1004	770		2004	375	Reissue filing fee	
	1005	160		2005	80	Provisional filing fee	

SUBTOTAL (1) (\$) 770

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims 41 - 20** = 21 x 18 = 378

Independent Claims 1 - 3** = 0 x 86 = 0

Multiple Dependent

Large Entity	Fee Code	Fee (\$)	Small Entity	Fee Code	Fee (\$)	Fee Description
	1202	18		2202	9	Claims in excess of 20
	1201	86		2201	42	Independent claims in excess of 3
	1203	290		2203	140	Multiple dependent claim, if not paid
	1204	86		2204	42	**Reissue independent claims over original patent
	1205	18		2205	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 378

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Fee Code	Fee (\$)	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
	1051	130		2051	65	Surcharge - late filing fee or oath	
	1052	50		2052	25	Surcharge - late provisional filing fee or cover sheet	
	1053	130		1053	130	Non-English Specification	
	1812	2,520		1812	2,520	For filing a request for reexamination	
	1804	920*		1804	920*	Requesting publication of SIR prior to Examiner action	
	1805	1,840*		1805	1,840*	Requesting publication of SIR after Examiner action	
	1251	110		2251	55	Extension for reply within first month	
	1252	420		2252	205	Extension for reply within second month	
	1253	950		2253	465	Extension for reply within third month	
	1254	1,480		2254	725	Extension for reply within fourth month	
	1255	2,010		2255	985	Extension for reply within fifth month	
	1401	330		2401	160	Notice of Appeal	
	1402	330		2402	160	Filing a brief in support of an appeal	
	1403	290		2403	140	Request for oral hearing	
	1451	1,510		1451	1,510	Petition to institute a public use proceeding	
	1452	110		2452	55	Petition to revive - unavoidable	
	1453	1,330		2453	650	Petition to revive - unintentional	
	1501	1,330		2501	650	Utility issue fee (or reissue)	
	1502	480		2502	235	Design issue fee	
	1503	640		2503	315	Plant issue fee	
	1460	130		1460	130	Petitions to the Commissioner	
	1807	50		1807	50	Petitions related to provisional applications	
	1806	180		1806	180	Submission of Information Disclosure Stmt	
	8021	40		8021	40	Recording each patent assignment per property (times number of properties)	
	1809	770		2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
	1810	770		2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
	1801	770		2801	375	Request for Continued Examination (RCE)	
	1802	900		1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Name (Print/Type) Irving Newman, Reg. No. 22,638

Signature

[Signature]

Registration No. (Attorney/Agent)

22,638

Complete (If applicable)

Telephone

(908) 231-2785

Date

12/04/03

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template